FDA Awaits GAO Report To Guide Behind-The-Counter Policy
This article was originally published in The Tan Sheet
Executive Summary
The Government Accountability Office's anticipated updated report on a behind-the-counter class of drugs will help shape FDA's policy, according to Connie T. Jung, senior policy advisor for Pharmacy Affairs